InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 193611

Tuesday, 10/14/2014 10:18:16 PM

Tuesday, October 14, 2014 10:18:16 PM

Post# of 345844

David Carbone - Peregrine Pharmaceuticals KOL cont'd...



First... didn't Peregrine head out to Australia last year for some Ballroom event? : )

.. well, here are the keynote speakers this time around and Dr. David Carbone may be the only one that stands out at first sight... but digging deeper it looks like just about everyone is involved re: IASLC and who is the upcoming President? You have it correct.. Dr. David Carbone- Peregrine Pharmaceuticals KOL


Dr Noelle O’Rourke
Clinical Oncology Consultant, Glasgow

IASLC : Patient Advocate Committee: Member

Kazuhiro Yasufuku
A/Prof of Surgery, Toronto General Hospital, Canada

Prof David Carbone
Medical Oncologist, The Ohio State University, U.S.A.

IASLC : President Elect
IASLC : Patient Advocate Committee : Board Liason


Dr Keith Kerr
Consultant Pathologist, University of Aberdeen, Scotland

IASLC : Pathology Committee (Board Liason)

Dr Billy W Loo
Radiation Oncologist, Stanford, California

IASLC : Publications Committee (Member)

Prof John K Field
Director of Research, Roy Castle, UK

IASLC : Prevention, Screening & Early Detection (Past Chair)

Natalie Doyle
Nurse Consultant, The Royal Marsden, UK

KeyNote Speakers above at ALCC:
http://www.alcc.net.au/

Keynote Speakers above and the committee listings from IASLC:
https://www.iaslc.org/about-us/committees

----------------------------------------------------

I also notice Martin Edelman is with IASLC @ Career Development Committee and remember, he leaves New Mexico to head back to MD... and he also was quoted:

"I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations,"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106609477&txt2find=martin|edelman

----------------------------------------------------

did Dr. Howard West ever return any messages or reply to anyone? He is also on the IASLC "Patient Advocate Committee -Member" and would like to be a fly on the wall there the last couple months...because all of my puzzle pieces say he will no longer be in this puzzle


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News